Conditions

This post was originally published on this site A combination of oral Lynparza (olaparib) and weekly chemotherapy can be safely given to heavily treated ovarian cancer patients and shows signs of efficacy, particularly among those with BRCA mutations, a Phase 1/2 trial shows. The findings suggest that weekly chemotherapy might be more suitable for these patients…

This post was originally published on this site A first patient has been given a combination of an investigational therapy, COTI-2, plus standard-of-care chemotherapy in an expanded Phase 1b/2a trial for gynecological and other solid tumors, Cotinga Pharmaceuticals, the potential treatment’s developer, announced. The clinical trial (NCT02433626) was first designed to evaluate the safety and…

This post was originally published on this site Precigen is preparing to launch a Phase 1 trial to test its investigational therapy PRGN-3005 UltraCAR-T for advanced, platinum-resistant ovarian cancer, after the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application. The open-label, dose-escalation study will assess the treatment’s safety and maximum tolerated dose.…

This post was originally published on this site Medications currently approved to treat some kinds of breast cancer — generally called CDK4/6 inhibitors — could be re-purposed to treat a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a study suggests. The study, “CDK4/6 inhibitors target SMARCA4-determined cyclin D1…

This post was originally published on this site Preliminary data from an ongoing Phase 1 trial suggest that Harpoon Therapeutics’ investigational therapy HPN424 is safe and effectively activates the immune system in metastatic castration resistant prostate cancer (mCRPC) patients. The multicenter, international, open-label study (NCT03577028) is assessing the safety, tolerability and overall stability and distribution of…

This post was originally published on this site The Prostate Cancer Foundation (PCF) has granted a $1 million Challenge Award to researchers from the Masonic Cancer Center at the University of Minnesota to support their investigations into new therapies for prostate cancer. With this award, the PCF hopes to accelerate the development of strategies to improve…

This post was originally published on this site Scientists from the Queen Mary University of London have received grants worth more than £2.5 million ($3.2 million), awarded by Prostate Cancer UK to advance prostate cancer research. The funds, which are part of the charity’s Research Innovation Awards scheme, aim to foster innovative and ambitious research projects across the…

This post was originally published on this site Adding the androgen receptor inhibitor Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression — assessed through radiological imaging — or death among metastatic hormone-sensitive prostate cancer patients, results of a Phase 3 trial show. The benefits were seen across multiple patient subgroups, regardless of initial…

This post was originally published on this site Prostate Cancer UK has awarded more than $355,000 (£275,000) to University of Birmingham researchers to develop a diagnostic tool that can measure the aggressiveness of a patient’s prostate cancer. The new technology will help physicians identify the best course of treatment for each patient. The grant is part…

This post was originally published on this site Aquablation is a safe and more efficient procedure to treat men with symptoms of benign prostatic hyperplasia (BPH) than is TURP, according to early results of the Phase 3 WATER trial (NCT02505919). Preliminary trial safety and efficacy findings were presented at the recent American Urological Association (AUA) Annual Meeting in…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved an under-the-skin formulation of Genentech‘s breast cancer treatment Herceptin (trastuzumab), called Herceptin Hylecta. Also by Genentech, the treatment consists of a combination of trastumuzab and recombinant human hyaluronidase PH20, a protein that helps deliver the antibody under the skin. “Over the past…